Dual therapy of vildagliptin and telmisartan on diabetic nephropathy in experimentally induced type 2 diabetes mellitus rats

Sharma, Ashish Kumar; Kanawat, Devendra Singh; Mishra, Akanksha; Dhakad, Prashant Kumar; Sharma, Prashant Kumar; Srivastava, Varnika; Joshi, Sneha; Joshi, Megha; Raikwar, Sachin Kumar; Kurmi, Muneem Kumar; Srinivasan, B.P.

doi:10.1177/1470320313475908

Cited by 15 publications

(12 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Improvement of the two previously mentioned parameters can be explained in our investigation by the significant increase of plasma active GLP-1 levels detected in the treated group when compared to corresponding value in the correlated non-treated group. These results agree with [57] who explained anti-diabetic hypoglycemic effect of Vildagliptin by improved insulin secretion and peripheral insulin sensitivity through binding covalently to the catalytic site of Sohair A. Saleh, el al.…”

Section: Vildagliptin-treated Groups (Type I and Type Ii)supporting

confidence: 92%

Role of Dipeptidyl Peptidase-4 Inhibitor in the Control of Glycemic State in Type I and Type II Diabetes Mellitus in Rats: A Comparative Study

Saleh¹,

Hanna²,

Gaafar

et al. 2018

The Medical Journal of Cairo University

View full text Add to dashboard Cite

Background: Incretin hormones; glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) have attracted considerable scientific and clinical interest due largely to their insulin-releasing and glucoselowering properties. Dipeptidyl peptidase-4 (DPP-4) is the enzyme responsible for cleavage and inactivation of GIP and GLP-1. Aim of Study:The present investigation was assigned to study and compare the effect of DPP-4 inhibitor (vildagliptin) on glycemic state in type I and type II diabetes mellitus in rats.Material and Methods: Fifty male albino rats of local strain were used. Rats were divided into three groups: Nondiabetic (10 rats); type I diabetic (non-treated, 10 rats and Vildagliptin-treated, 10 rats); type II diabetic (non-treated group, 10 rats and Vildagliptin-treated, 10 rats). Type I diabetes was induced by a single intraperitoneal injection (60mg/kg) of STZ dissolved in 0.2ml citrate buffer in adult 6 weeks old rats. 48h later fasting blood samples were taken from rat tail and rats with fasting blood glucose levels greater than 250mg/dl were considered diabetic type I. They were left for 30 days before assessment. Type II diabetes was induced by a single intra-peritoneal injection (90mg/kg) of STZ to a group of 2 days old pups. 6 weeks later, fasting blood samples were taken from rat tail and rats with fasting blood glucose level ≥ 160mg/dl were considered as diabetic type II, they were left for 30 days before assessment. In both treated groups rats were treated daily with Vildagliptin (5mg/kg) by oral gavage for 30 days. At the end of the experiment, retro-orbital fasting blood sample was taken for measurement of serum glucose, serum insulin, glycated hemoglobin (HbA1c), plasma GLP-1 levels, lipid profile, malondialdehyde and total antioxidant capacity. Homeostasis model assessment of insulin resistance (HOMA-IR) index was calculated.Results: Serum glucose, blood HbA1c, serum cholesterol, triglycerides (TG), low density lipoprotein-cholesterol (LDLcholesterol) and malondialdehyde (MDA) were significantly higher in type I and type II diabetic non-treated groups when Conclusion: Vildagliptin treatment is a good choice for type II diabetes treatment and has beneficial effects in type I diabetes.

show abstract

Section: Vildagliptin-treated Groups (Type I and Type Ii)supporting

confidence: 92%

Role of Dipeptidyl Peptidase-4 Inhibitor in the Control of Glycemic State in Type I and Type II Diabetes Mellitus in Rats: A Comparative Study

Saleh¹,

Hanna²,

Gaafar

et al. 2018

The Medical Journal of Cairo University

View full text Add to dashboard Cite

show abstract

“…Some studies revealed an elevation of urea and plasma Cr and reduction of plasma albumin levels in diabetic rats (16,17,19). The results of Sharma et al study indicate that BUN and serum Cr level significantly increased in type 2 diabetic rats (20). Likewise, Viswanathan et al showed a significant serum albumin reduction in type 2 of diabetes (21).…”

Section: Discussionmentioning

confidence: 98%

Preventive effects of betulinic acid on streptozotocinnicotinamide induced diabetic nephropathy in male mouse

et al. 2016

View full text Add to dashboard Cite

“…Telmisartan is used mainly due to its effect on RAS, but the effects on activate PPAR-γ has been explored in some studies. According to these studies, PPAR-γ activation appears to be an innovative mechanism to mediate the bene cial effects of inhibitors angiotensin receptors [20,21,34,36].…”

Section: Discussionmentioning

confidence: 99%

Renin–angiotensin–aldosterone system blockade with telmisartan prevents the decline in cardiac contractility orchiectomy-dependent in SHR: role of PPAR-γ activation

Silva

Almenara

Birocale

et al. 2021

Preprint

View full text Add to dashboard Cite

The present study aimed to investigate the beneficial role of AT1 receptor blockade and PPAR-γ activation in preventing cardiac contractile changes in hypertensive animals (SHR) with testosterone deficiency. Rats were divided into a control group (sham), orchiectomized (OCT), orchiectomized that received telmisartan (OCT + Tel) or telmisartan plus PPAR-γ antagonist (OCT + Tel + BADGE). After 8 weeks, contractility of isolated papillary muscles was evaluated. The OCT group showed a reduction in the contraction force, avoided in the OCT + Tel and Tel + BADGE groups. Post-pause potentiation (PPP) was similar in the Sham, OCT and OCT + Tel group, suggesting prevention of sarcoplasmic reticulum activity. In contrast, PPP in the OCT + Tel + BADGE group decreased. The reduction in response to calcium or isoproterenol in the OCT group was prevented in the OCT + Tel and Tel + BADGE group. The influx of calcium, assessed indirectly, although it was similar in the OCT and Sham groups, increased both in the OCT + Tel groups and in the OCT + Tel + BADGE groups. SERCA2a protein expression was increased in the OCT group, which was avoided in the OCT + Tel and Tel + BADGE group. NCX expression was increased in the Tel + BADGE group compared to OCT + Tel and sham. Our results suggest that AT1 receptor blockade with telmisartan prevents compromised papillary muscle contractility in SHR. Moreover, it has been shown that the activation of PPAR-γ adds benefits to the inhibition of renin-angiotensin system with telmisartan in preventing harmful effects on the contractility of hypertensive rats with testosterone deficiency.

show abstract

Dual therapy of vildagliptin and telmisartan on diabetic nephropathy in experimentally induced type 2 diabetes mellitus rats

Cited by 15 publications

References 12 publications

Role of Dipeptidyl Peptidase-4 Inhibitor in the Control of Glycemic State in Type I and Type II Diabetes Mellitus in Rats: A Comparative Study

Role of Dipeptidyl Peptidase-4 Inhibitor in the Control of Glycemic State in Type I and Type II Diabetes Mellitus in Rats: A Comparative Study

Preventive effects of betulinic acid on streptozotocinnicotinamide induced diabetic nephropathy in male mouse

Renin–angiotensin–aldosterone system blockade with telmisartan prevents the decline in cardiac contractility orchiectomy-dependent in SHR: role of PPAR-γ activation

Contact Info

Product

Resources

About